CHANGES OF PLASMA COMPLEMENT C3B, C5B AND VWF, ADAMTS13 IN PATIENTS WITH THROMBOTIC MICROANGIOPATHY AFTER HEMATOPOIETIC STEM-CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Han Y. 06/09/16; 133060; E1511
Prof. Yue Han
Contributions
Contributions
Abstract
Abstract: E1511
Type: Eposter Presentation
Background
Transplant-associated microangiopathy (TMA) is an uncommon but devastating complication in patients undergoing hematopoietic stem-cell transplantation (HSCT). It may be confused with severe graft-versus-host disease (GVHD), infection, and other transplant related thrombotic diseases. Limited studies have shown the changes in plasma VWF/ADAMTS13 or complement activation markers in patients after HSCT. However, the role of VWF/ADAMTS13 and complement activation in patients with TMA and GVHD is not fully understood.
Aims
Current study is to investigate the alterations of plasma levels of C3b, C5b and VWF/ADAMTS13 in patients with TMA and to explore their roles in the pathogenesis and early diagnosis of transplant-associated TMA.
Methods
From 2011 to 2014, 14 patients with TMA were enrolled into the study in a single medical center. 71 other patients following HSCT were recruited as control subjects including 11 cases of hepatic vein occlusion disease (VOD), 20 cases of severe infections, 20 cases of severe II-IV° GVHD and 20 cases without complications. Blood sample was collected before transplantation and at the onset of transplantation related complication. Fluorescence resonance energy transfer substrate (FRETS)-VWF73 assay detected plasma ADAMTS13 activity. Collagen-binding assay and latex immunoassay determined VWF activity and VWF antigen, respectively. Plasma VWF multimer was determined by agarose gel electrophoresis and Western blot. Plasma levels of complement C3b and C5b were measured with ELISA.
Results
Compared with the levels before transplantation, plasma ADAMTS13 activity and VWF antigen or activity in the patients with TMA did not differ from those who developed TMA, with infection or GVHD or without any complication (p > 0.05). However, plasma ADAMTS13 activity decreased and the ratio of VWF antigen/activity increased significantly in patients with VOD (p < 0.05). Plasma VWF multimer distribution was similar in patients with infection, GVHD or without complication, but ultralarge multimers of VWF was present in patients with TMA and VOD. Plasma levels of complement C3b was increased in patients after HSCT (198.46 ng/ml ±14.78 ng/ml) compared with healthy subjects (85.02 ng/ml±8.50ng/ml) (p < 0.05), but exhibited no difference in the other groups. Plasma C3b increased significantly in patients with TMA and GVHD (p<0.05). The plasma levels of C3b were higher in the TMA group (480.70 ng/ml±66.76ng/ml) than the GVHD group (298.50 ng/ml ±32.06 ng/) (p < 0.05). Also, plasma levels of C5b in patients with TMA were significantly increased (1059.49 ng/ml ±85.57 ng/ml) as compared with those before transplantation (653.19ng/ml ±44.91ng/ml) and other groups (p < 0.05).
Conclusion
We conclude that plasma ADAMTS 13 activity and the ratio of VWF antigen/activity remained stable in the patients with transplant-associated TMA, but the levels of complement C3b and C5b, particularly the C5b, increased significantly, suggesting the critical role of complement pathway in the pathogenesis of TMA. C5b may be a specific biomarker for early diagnosis of TMA but C3b is a marker for both TMA and GVHD.
Session topic: E-poster
Keyword(s): ADAMTS13, Complement, Hematopoietic cell transplantation, Thrombotic microangiopathy
Type: Eposter Presentation
Background
Transplant-associated microangiopathy (TMA) is an uncommon but devastating complication in patients undergoing hematopoietic stem-cell transplantation (HSCT). It may be confused with severe graft-versus-host disease (GVHD), infection, and other transplant related thrombotic diseases. Limited studies have shown the changes in plasma VWF/ADAMTS13 or complement activation markers in patients after HSCT. However, the role of VWF/ADAMTS13 and complement activation in patients with TMA and GVHD is not fully understood.
Aims
Current study is to investigate the alterations of plasma levels of C3b, C5b and VWF/ADAMTS13 in patients with TMA and to explore their roles in the pathogenesis and early diagnosis of transplant-associated TMA.
Methods
From 2011 to 2014, 14 patients with TMA were enrolled into the study in a single medical center. 71 other patients following HSCT were recruited as control subjects including 11 cases of hepatic vein occlusion disease (VOD), 20 cases of severe infections, 20 cases of severe II-IV° GVHD and 20 cases without complications. Blood sample was collected before transplantation and at the onset of transplantation related complication. Fluorescence resonance energy transfer substrate (FRETS)-VWF73 assay detected plasma ADAMTS13 activity. Collagen-binding assay and latex immunoassay determined VWF activity and VWF antigen, respectively. Plasma VWF multimer was determined by agarose gel electrophoresis and Western blot. Plasma levels of complement C3b and C5b were measured with ELISA.
Results
Compared with the levels before transplantation, plasma ADAMTS13 activity and VWF antigen or activity in the patients with TMA did not differ from those who developed TMA, with infection or GVHD or without any complication (p > 0.05). However, plasma ADAMTS13 activity decreased and the ratio of VWF antigen/activity increased significantly in patients with VOD (p < 0.05). Plasma VWF multimer distribution was similar in patients with infection, GVHD or without complication, but ultralarge multimers of VWF was present in patients with TMA and VOD. Plasma levels of complement C3b was increased in patients after HSCT (198.46 ng/ml ±14.78 ng/ml) compared with healthy subjects (85.02 ng/ml±8.50ng/ml) (p < 0.05), but exhibited no difference in the other groups. Plasma C3b increased significantly in patients with TMA and GVHD (p<0.05). The plasma levels of C3b were higher in the TMA group (480.70 ng/ml±66.76ng/ml) than the GVHD group (298.50 ng/ml ±32.06 ng/) (p < 0.05). Also, plasma levels of C5b in patients with TMA were significantly increased (1059.49 ng/ml ±85.57 ng/ml) as compared with those before transplantation (653.19ng/ml ±44.91ng/ml) and other groups (p < 0.05).
Conclusion
We conclude that plasma ADAMTS 13 activity and the ratio of VWF antigen/activity remained stable in the patients with transplant-associated TMA, but the levels of complement C3b and C5b, particularly the C5b, increased significantly, suggesting the critical role of complement pathway in the pathogenesis of TMA. C5b may be a specific biomarker for early diagnosis of TMA but C3b is a marker for both TMA and GVHD.
Session topic: E-poster
Keyword(s): ADAMTS13, Complement, Hematopoietic cell transplantation, Thrombotic microangiopathy
Abstract: E1511
Type: Eposter Presentation
Background
Transplant-associated microangiopathy (TMA) is an uncommon but devastating complication in patients undergoing hematopoietic stem-cell transplantation (HSCT). It may be confused with severe graft-versus-host disease (GVHD), infection, and other transplant related thrombotic diseases. Limited studies have shown the changes in plasma VWF/ADAMTS13 or complement activation markers in patients after HSCT. However, the role of VWF/ADAMTS13 and complement activation in patients with TMA and GVHD is not fully understood.
Aims
Current study is to investigate the alterations of plasma levels of C3b, C5b and VWF/ADAMTS13 in patients with TMA and to explore their roles in the pathogenesis and early diagnosis of transplant-associated TMA.
Methods
From 2011 to 2014, 14 patients with TMA were enrolled into the study in a single medical center. 71 other patients following HSCT were recruited as control subjects including 11 cases of hepatic vein occlusion disease (VOD), 20 cases of severe infections, 20 cases of severe II-IV° GVHD and 20 cases without complications. Blood sample was collected before transplantation and at the onset of transplantation related complication. Fluorescence resonance energy transfer substrate (FRETS)-VWF73 assay detected plasma ADAMTS13 activity. Collagen-binding assay and latex immunoassay determined VWF activity and VWF antigen, respectively. Plasma VWF multimer was determined by agarose gel electrophoresis and Western blot. Plasma levels of complement C3b and C5b were measured with ELISA.
Results
Compared with the levels before transplantation, plasma ADAMTS13 activity and VWF antigen or activity in the patients with TMA did not differ from those who developed TMA, with infection or GVHD or without any complication (p > 0.05). However, plasma ADAMTS13 activity decreased and the ratio of VWF antigen/activity increased significantly in patients with VOD (p < 0.05). Plasma VWF multimer distribution was similar in patients with infection, GVHD or without complication, but ultralarge multimers of VWF was present in patients with TMA and VOD. Plasma levels of complement C3b was increased in patients after HSCT (198.46 ng/ml ±14.78 ng/ml) compared with healthy subjects (85.02 ng/ml±8.50ng/ml) (p < 0.05), but exhibited no difference in the other groups. Plasma C3b increased significantly in patients with TMA and GVHD (p<0.05). The plasma levels of C3b were higher in the TMA group (480.70 ng/ml±66.76ng/ml) than the GVHD group (298.50 ng/ml ±32.06 ng/) (p < 0.05). Also, plasma levels of C5b in patients with TMA were significantly increased (1059.49 ng/ml ±85.57 ng/ml) as compared with those before transplantation (653.19ng/ml ±44.91ng/ml) and other groups (p < 0.05).
Conclusion
We conclude that plasma ADAMTS 13 activity and the ratio of VWF antigen/activity remained stable in the patients with transplant-associated TMA, but the levels of complement C3b and C5b, particularly the C5b, increased significantly, suggesting the critical role of complement pathway in the pathogenesis of TMA. C5b may be a specific biomarker for early diagnosis of TMA but C3b is a marker for both TMA and GVHD.
Session topic: E-poster
Keyword(s): ADAMTS13, Complement, Hematopoietic cell transplantation, Thrombotic microangiopathy
Type: Eposter Presentation
Background
Transplant-associated microangiopathy (TMA) is an uncommon but devastating complication in patients undergoing hematopoietic stem-cell transplantation (HSCT). It may be confused with severe graft-versus-host disease (GVHD), infection, and other transplant related thrombotic diseases. Limited studies have shown the changes in plasma VWF/ADAMTS13 or complement activation markers in patients after HSCT. However, the role of VWF/ADAMTS13 and complement activation in patients with TMA and GVHD is not fully understood.
Aims
Current study is to investigate the alterations of plasma levels of C3b, C5b and VWF/ADAMTS13 in patients with TMA and to explore their roles in the pathogenesis and early diagnosis of transplant-associated TMA.
Methods
From 2011 to 2014, 14 patients with TMA were enrolled into the study in a single medical center. 71 other patients following HSCT were recruited as control subjects including 11 cases of hepatic vein occlusion disease (VOD), 20 cases of severe infections, 20 cases of severe II-IV° GVHD and 20 cases without complications. Blood sample was collected before transplantation and at the onset of transplantation related complication. Fluorescence resonance energy transfer substrate (FRETS)-VWF73 assay detected plasma ADAMTS13 activity. Collagen-binding assay and latex immunoassay determined VWF activity and VWF antigen, respectively. Plasma VWF multimer was determined by agarose gel electrophoresis and Western blot. Plasma levels of complement C3b and C5b were measured with ELISA.
Results
Compared with the levels before transplantation, plasma ADAMTS13 activity and VWF antigen or activity in the patients with TMA did not differ from those who developed TMA, with infection or GVHD or without any complication (p > 0.05). However, plasma ADAMTS13 activity decreased and the ratio of VWF antigen/activity increased significantly in patients with VOD (p < 0.05). Plasma VWF multimer distribution was similar in patients with infection, GVHD or without complication, but ultralarge multimers of VWF was present in patients with TMA and VOD. Plasma levels of complement C3b was increased in patients after HSCT (198.46 ng/ml ±14.78 ng/ml) compared with healthy subjects (85.02 ng/ml±8.50ng/ml) (p < 0.05), but exhibited no difference in the other groups. Plasma C3b increased significantly in patients with TMA and GVHD (p<0.05). The plasma levels of C3b were higher in the TMA group (480.70 ng/ml±66.76ng/ml) than the GVHD group (298.50 ng/ml ±32.06 ng/) (p < 0.05). Also, plasma levels of C5b in patients with TMA were significantly increased (1059.49 ng/ml ±85.57 ng/ml) as compared with those before transplantation (653.19ng/ml ±44.91ng/ml) and other groups (p < 0.05).
Conclusion
We conclude that plasma ADAMTS 13 activity and the ratio of VWF antigen/activity remained stable in the patients with transplant-associated TMA, but the levels of complement C3b and C5b, particularly the C5b, increased significantly, suggesting the critical role of complement pathway in the pathogenesis of TMA. C5b may be a specific biomarker for early diagnosis of TMA but C3b is a marker for both TMA and GVHD.
Session topic: E-poster
Keyword(s): ADAMTS13, Complement, Hematopoietic cell transplantation, Thrombotic microangiopathy
{{ help_message }}
{{filter}}